Polysaccharide adjuvants for use in protein-based or rna-based vaccines
AssigneesChildren's Medical Center Corporation, The Brigham and Women's Hospital, Inc.
InventorsIvan Zanoni, Jeffrey M. Karp, Bryan Laulicht, Kautilya Jena
Life of this patent
Estimating the term…
Abstract
Provided herein are adjuvantation systems comprising mannan (e.g., a plant mannan or a fungal manna) for use with Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus antigen or a nucleic acid encoding the Beta coronavirus antigen.
Claims99
An immunogenic composition comprising:
- (i) an adjuvantation system comprising a mannan;
- and
- (ii) a nucleic acid encoding an antigen.
An immunogenic composition comprising:
- (i) an adjuvantation system comprising a plant mannan;
- and
- (ii) an antigen.
A method of inducing an immune response against a pathogen in a subject in need thereof, the method comprising administering to the subject:
- (i) an adjuvantation system comprising a mannan, and
- (ii) a nucleic acid encoding an antigen.
The method of any one of claims 443-62, wherein the adjuvantation system and the nucleic acid are admixed.
A method of inducing an immune response against a pathogen in a subject in need thereof, the method comprising administering to the subject:
- (i) an adjuvantation system comprising a plant mannan, and
- (ii) an antigen.
An adjuvantation system comprising a plant mannan for use in inducing an immune response against a pathogen in a subject in need thereof.
Dependencies are inferred from the claim text.